These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Depression and Anxiety--SMi's second conference. 28-29 June 2006, London, UK. Kneller S IDrugs; 2006 Sep; 9(9):614-8. PubMed ID: 16952066 [No Abstract] [Full Text] [Related]
4. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders. Macauley D; Al-Shamahi A IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499 [No Abstract] [Full Text] [Related]
5. Adaptive designs in clinical drug development--SMi's third annual conference. 4-5 February 2009, London, UK. Padhiar M IDrugs; 2009 Apr; 12(4):230-2. PubMed ID: 19350466 [No Abstract] [Full Text] [Related]
6. Central nervous system drug development, basic, and clinical research: thinking outside the box. Klein DF; Glick ID; Shader RI J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701 [No Abstract] [Full Text] [Related]
7. Use of predictive models in CNS diseases. Gomeni R Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008 [TBL] [Abstract][Full Text] [Related]
8. Axel Unterbeck on memory, cognition and the development of CNS drugs. Interview by Steve Carney. Unterbeck A Drug Discov Today; 2005 Feb; 10(3):165-8. PubMed ID: 15708528 [No Abstract] [Full Text] [Related]
9. Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK. Beecher N IDrugs; 2009 Sep; 12(9):558-60. PubMed ID: 19697274 [No Abstract] [Full Text] [Related]
10. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases. Al-Shamahi A; Kirkham K; Hookes L IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211 [TBL] [Abstract][Full Text] [Related]
11. Molecular imaging as a de-risking tool: coming into focus? Mullard A Nat Rev Drug Discov; 2013 Apr; 12(4):251-2. PubMed ID: 23535924 [No Abstract] [Full Text] [Related]
12. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
14. Clinical trials in cancer - SMi's Seventh Annual Conference. Fakorede A IDrugs; 2008 Sep; 11(9):627-9. PubMed ID: 18763208 [No Abstract] [Full Text] [Related]
15. Clinical Trials in CNS--SMi Conference. Harris S IDrugs; 2005 Jan; 8(1):25-8. PubMed ID: 15650937 [No Abstract] [Full Text] [Related]
16. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases. Bishop KM Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711 [TBL] [Abstract][Full Text] [Related]
17. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. Yokley BH; Hartman M; Slusher BS ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461 [TBL] [Abstract][Full Text] [Related]